Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation

IntroductionTriple-negative breast cancer (TNBC) is a challenging subtype of breast cancer to treat because it lacks the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2). A significant majority of deaths related to cancer are cause...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Anisha Jain, Anil Kumar Belagal Motatis, Chandan Dharmashekar, Bhargav Shreevatsa, Siddesh VS, Monisha Srinivas, Sudhanva Muddenahalli Srinivasa, Ashwini P, M. N. Nagendra Prasad, Rafael Rosell, Jordi Codony-Servat, Shobith Rangappa, Muzaffar Iqbal, Kasim Sakran Abass, Raghavendra G. Amachawadi, Victor Stupin, Shiva Prasad Kollur, Chandan Shivamallu, Ekaterina Silina
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-10-01
Serija:	Frontiers in Oncology
Teme:	risperidone triple-negative breast cancer angiogenesis drug repurposing VEGFR2
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1645905/full
Oznake:	Označite Brez oznak, prvi označite!